Clinical Trial Update: Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sunitinib in patients with recurrent or persistent uterine leiomyosarcoma and recurrent uterine sarcoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Uterine Leiomyosarcoma
• Uterine Sarcoma

Drugs mentioned

• Sunitinib (sunitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Uterine Sarcoma, Uterine Leiomyosarcoma | Phase 2 | Status: COMPLETED